Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HepaVaxx B
- Development stage
- Unknown
- Lead developer
- CJ CheilJedang
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HepaVaxx B is a recombinant hepatitis B vaccine containing purified hepatitis B surface antigen (HBsAg). Developed by CJ CheilJedang, the vaccine is produced using recombinant DNA technology in *Saccharomyces cerevisiae* (yeast) cells. It is indicated for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV). The vaccine works by stimulating the host's immune system to produce specific neutralizing antibodies (anti-HBs) against the surface antigen, thereby providing long-term protection against HBV-related diseases, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. It is typically administered as a series of intramuscular injections and is widely used in national immunization programs.
- Brand names
- HepaVaxx BHepavax-B
- Other names
- Hepatitis B vaccine (recombinant)Recombinant Hepatitis B Surface Antigen Vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on HepaVaxx B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HepaVaxx B.